Halozyme Therapeutics (HALO) Receivables - Other (2019 - 2024)

Halozyme Therapeutics (HALO) has 6 years of Receivables - Other data on file, last reported at $20.3 million in Q4 2024.

• On a quarterly basis, Receivables - Other rose 1930.0% year-over-year to $20.3 million in Q4 2024; TTM through Dec 2024 was $20.3 million, a 1930.0% increase from a year earlier, with the FY2024 full-year figure at $20.3 million, up 1930.0% from the prior year.
• Receivables - Other for Q4 2024 stood at $20.3 million, up from $1.0 million in the prior quarter.
• Over the last five years, Receivables - Other for HALO reached as high as $69.2 million in Q3 2022 and fell as low as $1.0 million in Q4 2023.
• Historically, Receivables - Other has averaged $23.9 million across 5 years, with a median of $22.4 million in 2023.
• Across the five-year window, Receivables - Other tumbled 95.23% in 2023 and surged 1930.0% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $7.0 million in 2020, then surged by 328.57% to $30.0 million in 2021, then surged by 130.56% to $69.2 million in 2022, then tumbled by 98.55% to $1.0 million in 2023, then jumped by 1930.0% to $20.3 million in 2024.
• Per Business Quant data, the three most recent Receivables - Other figures were $20.3 million in Q4 2024, $1.0 million in Q4 2023, and $3.3 million in Q3 2023.